Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X6EM
|
|||
| Former ID |
DIB007269
|
|||
| Drug Name |
T2c-001
|
|||
| Synonyms |
T2c-001-AMI; T2c-001-CHD; T2c-001-DCM; T2c-001-SW; Autologous bone marrow-derived endothelial progenitor cell therapy, Goethe University/t2cure; Autologous endothelial progenitor cells (myocardial infarction), Goethe University/t2cure; Endothelial progenitor cell therapy (ischemia), Goethe University/t2cure
Click to Show/Hide
|
|||
| Indication | Congestive heart failure [ICD-11: BD10; ICD-10: I50.0; ICD-9: 428] | Phase 2 | [1] | |
| Company |
Johann Wolfgang Goethe-Universitat Frankfurt am Main
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | T-cells (T-cells) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01693042) Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure. U.S. National Institutes of Health. | |||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.